Mespirenone

Mespirenone (INN) (developmental code name ZK-94679), also known as Δ1-15β,16β-methylenespironolactone, is a steroidal antimineralocorticoid of the spirolactone group related to spironolactone that was never marketed.[1][2] Animal research found that it was 3.3-fold more potent as an antimineralocorticoid relative to spironolactone.[3] In addition to its antimineralocorticoid properties, mespirenone is also a progestogen, antigonadotropin, and antiandrogen.[2][4] It is 2- to 3-fold as potent as spironolactone as a progestogen and antigonadotropin but its antiandrogenic activity is markedly reduced and weak (though still of significance) in comparison.[4][5] Mespirenone is also a potent and specific enzyme inhibitor of 18-hydroxylase and thus of mineralocorticoid biosynthesis.[6] The drug was under development by Schering (now Bayer Schering Pharma) and reached phase II clinical trials but was discontinued in 1989.[7]

Mespirenone
Clinical data
Routes of
administration
Oral
ATC code
  • None
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC25H30O4S
Molar mass426.57 g·mol−1
3D model (JSmol)

See also

References

  1. J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 775–. ISBN 978-1-4757-2085-3.
  2. Losert W, Bittler D, Buse M, Casals-Stenzel J, Haberey M, Laurent H, Nickisch K, Schillinger E, Wiechert R (1986). "Mespirenone and other 15,16-methylene-17-spirolactones, a new type of steroidal aldosterone antagonists". Arzneimittelforschung. 36 (11): 1583–600. PMID 3028435.
  3. Arzneimittel-Forschung. Editio Cantor. 1991.
  4. Nishino Y, Schröder H, el Etreby MF (1988). "Experimental studies on the endocrine side effects of new aldosterone antagonists". Arzneimittelforschung. 38 (12): 1800–5. PMID 3245852.
  5. Opoku J, Kalimi M, Agarwal M, Qureshi D (1991). "Effect of a new mineralocorticoid antagonist mespirenone on aldosterone-induced hypertension". Am. J. Physiol. 260 (2 Pt 1): E269–71. PMID 1996630.
  6. Weindel K, Lewicka S, Vecsei P (1991). "Inhibitory effects of the novel anti-aldosterone compound mespirenone on adrenocortical steroidogenesis in vitro". Arzneimittelforschung. 41 (9): 946–9. PMID 1796922.
  7. Eckhard Ottow; Hilmar Weinmann (8 September 2008). Nuclear Receptors as Drug Targets. John Wiley & Sons. pp. 410–. ISBN 978-3-527-62330-3.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.